ATE453645T1 - Verfahren zur herstellung von pyrrolotriazinverbindungen, die sich als kinaseinhibitoren eignen - Google Patents
Verfahren zur herstellung von pyrrolotriazinverbindungen, die sich als kinaseinhibitoren eignenInfo
- Publication number
- ATE453645T1 ATE453645T1 AT03781756T AT03781756T ATE453645T1 AT E453645 T1 ATE453645 T1 AT E453645T1 AT 03781756 T AT03781756 T AT 03781756T AT 03781756 T AT03781756 T AT 03781756T AT E453645 T1 ATE453645 T1 AT E453645T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- producing
- kinase inhibitors
- compounds suitable
- pyrrolotriazine compounds
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000003921 pyrrolotriazines Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 abstract 1
- SHCRKMNTWSCEBT-UHFFFAOYSA-N N1N=NC=C2N=CC=C21 Chemical group N1N=NC=C2N=CC=C21 SHCRKMNTWSCEBT-UHFFFAOYSA-N 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 238000005576 amination reaction Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 238000007363 ring formation reaction Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/50—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/289,010 US6867300B2 (en) | 2000-11-17 | 2002-11-06 | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| PCT/US2003/035220 WO2004043912A2 (en) | 2002-11-06 | 2003-11-03 | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE453645T1 true ATE453645T1 (de) | 2010-01-15 |
Family
ID=32312096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03781756T ATE453645T1 (de) | 2002-11-06 | 2003-11-03 | Verfahren zur herstellung von pyrrolotriazinverbindungen, die sich als kinaseinhibitoren eignen |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6867300B2 (de) |
| EP (1) | EP1562949B1 (de) |
| JP (1) | JP4662775B2 (de) |
| KR (1) | KR20050084961A (de) |
| CN (1) | CN100360532C (de) |
| AT (1) | ATE453645T1 (de) |
| AU (1) | AU2003287514A1 (de) |
| BR (1) | BR0316056A (de) |
| CA (1) | CA2505365A1 (de) |
| CO (1) | CO5560547A2 (de) |
| DE (1) | DE60330800D1 (de) |
| ES (1) | ES2337571T3 (de) |
| MX (1) | MXPA05004748A (de) |
| PL (1) | PL377112A1 (de) |
| TW (1) | TWI290555B (de) |
| WO (1) | WO2004043912A2 (de) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6982265B1 (en) * | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| US6670357B2 (en) * | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| US6867300B2 (en) * | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| TW200300350A (en) * | 2001-11-14 | 2003-06-01 | Bristol Myers Squibb Co | C-5 modified indazolylpyrrolotriazines |
| PT1497019E (pt) | 2002-04-23 | 2015-09-10 | Bristol Myers Squibb Co | Compostos de pirrolotriazina anilina úteis como inibidores de quinase |
| US7388009B2 (en) | 2002-04-23 | 2008-06-17 | Bristol-Myers Squibb Company | Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors |
| TW200306841A (en) | 2002-04-23 | 2003-12-01 | Bristol Myers Squibb Co | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
| TW200401638A (en) * | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
| TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| TW200420565A (en) | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| JP2006516653A (ja) | 2003-02-05 | 2006-07-06 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤ピロロトリアジンの製造方法 |
| US7102001B2 (en) | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
| US20060014741A1 (en) * | 2003-12-12 | 2006-01-19 | Dimarco John D | Synthetic process, and crystalline forms of a pyrrolotriazine compound |
| MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| US7064203B2 (en) | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
| US7829720B2 (en) | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
| TWI415635B (zh) | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
| US7102002B2 (en) | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US7432373B2 (en) * | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7253167B2 (en) * | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
| TW200600513A (en) * | 2004-06-30 | 2006-01-01 | Bristol Myers Squibb Co | A method for preparing pyrrolotriazine compounds |
| US7102003B2 (en) * | 2004-07-01 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| US7504521B2 (en) * | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
| TW200618803A (en) | 2004-08-12 | 2006-06-16 | Bristol Myers Squibb Co | Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors |
| EP1812439B2 (de) † | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinaseinhibitoren |
| US7151176B2 (en) * | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| US7514435B2 (en) * | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7348325B2 (en) * | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| WO2007064931A2 (en) | 2005-12-02 | 2007-06-07 | Bayer Healthcare Llc | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| PE20070855A1 (es) | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
| US8063208B2 (en) | 2006-02-16 | 2011-11-22 | Bristol-Myers Squibb Company | Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol |
| JP5693239B2 (ja) | 2008-01-23 | 2015-04-01 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ４−ピリジノン化合物および癌についてのその使用 |
| ES2539620T3 (es) | 2008-12-19 | 2015-07-02 | Cephalon, Inc. | Pirrolotriazina como inhibidor de ALK y de JAK2 |
| WO2012031057A1 (en) | 2010-09-01 | 2012-03-08 | Bristol-Myers Squibb Company | Bms- 582949 for the treatment of resistant rheumatic disease |
| CN102153558B (zh) * | 2011-02-23 | 2012-11-21 | 扬州永济医药新技术有限公司 | 多靶点抗肿瘤抑制剂2-氨吡咯-三嗪的衍生物及其合成方法 |
| US9724352B2 (en) | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
| CN103450204B (zh) | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途 |
| CN104003990B (zh) * | 2013-02-21 | 2017-09-15 | 江苏先声药业有限公司 | 杂环胺类Hedgehog信号通路抑制剂 |
| US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| CN104788460B (zh) * | 2015-03-27 | 2016-11-09 | 陕西师范大学 | 4-芳氨基吡咯并[2,1-f][1,2,4]三嗪衍生物的制备方法 |
| WO2019168874A1 (en) | 2018-02-27 | 2019-09-06 | The Research Foundation For The State University Of New York | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| CN108516977A (zh) * | 2018-07-10 | 2018-09-11 | 刘凤娟 | 一种用于治疗恶性肿瘤的map激酶抑制剂的合成方法 |
| CN111234067B (zh) * | 2018-11-29 | 2021-08-03 | 中国石油化工股份有限公司 | 用于烯烃聚合的固体催化剂组分和催化剂及其应用 |
| CN113372263B (zh) * | 2021-05-21 | 2022-04-19 | 温州医科大学 | 一种2-氯-3-胺基萘醌化合物的制备方法 |
| CN113292503B (zh) * | 2021-05-22 | 2022-05-13 | 台州市第一人民医院 | 一种2-溴-3-胺基萘醌化合物的制备方法 |
| IL315733A (en) | 2022-04-08 | 2024-11-01 | SHY Therapeutics LLC | Compounds that Interact with RAS Superfamily Proteins for the Treatment of Cancer, Inflammatory, Basoplastic, and Fibrotic Diseases |
| CN116789674B (zh) * | 2022-08-24 | 2024-05-24 | 杭州高光制药有限公司 | Nlrp3炎性小体抑制剂 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4908056A (en) | 1986-04-25 | 1990-03-13 | E. I. Du Pont De Nemours And Company | Heterocyclic acyl sulfonamides |
| DE59500788D1 (de) | 1994-05-03 | 1997-11-20 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
| CA2163399A1 (en) | 1994-11-24 | 1996-05-25 | Katsuhiro Kawano | Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor |
| IL118544A (en) | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | History of imidazole, the process for their preparation and the pharmaceutical preparations containing them |
| PT778277E (pt) | 1995-12-08 | 2003-11-28 | Pfizer | Derivados heterociclicos substituidos como antagonistas do crf |
| PL187516B1 (pl) | 1996-01-11 | 2004-07-30 | Smithkline Beecham Corp | Nowe podstawione pochodne imidazolu, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca te związki |
| GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| US20010007867A1 (en) | 1999-12-13 | 2001-07-12 | Yuhpyng L. Chen | Substituted 6,5-hetero-bicyclic derivatives |
| JP3621706B2 (ja) | 1996-08-28 | 2005-02-16 | ファイザー・インク | 置換された６，５―ヘテロ―二環式誘導体 |
| US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| US5945418A (en) | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| IL132736A0 (en) | 1997-05-22 | 2001-03-19 | Searle & Co | 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors |
| US6087496A (en) | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
| US6251914B1 (en) | 1997-07-02 | 2001-06-26 | Smithkline Beecham Corporation | Cycloalkyl substituted imidazoles |
| WO1999024033A1 (en) | 1997-11-12 | 1999-05-20 | Shionogi & Co., Ltd. | Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds |
| US6130235A (en) | 1998-05-22 | 2000-10-10 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| MXPA01002173A (es) | 1998-08-28 | 2003-07-14 | Scios Inc | Inhibidores de p38-alfa cinasa. |
| ATE232205T1 (de) | 1998-10-01 | 2003-02-15 | Astrazeneca Ab | Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird |
| GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
| JP4649046B2 (ja) | 1999-05-21 | 2011-03-09 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼのピロロトリアジン阻害剤 |
| US6787545B1 (en) | 1999-08-23 | 2004-09-07 | Shiongi & Co., Ltd. | Pyrrolotriazine derivatives having spla2-inhibitory activities |
| GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
| CO5271670A1 (es) | 1999-10-29 | 2003-04-30 | Pfizer Prod Inc | Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas |
| ES2237470T3 (es) | 1999-11-10 | 2005-08-01 | Ortho-Mcneil Pharmaceutical, Inc. | 2-aril-3-(heteroaril)-imidazo(1,2-alfa)pirimidinas sustituidas; y composiciones farmaceuticas y procedimientos asociados. |
| US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
| US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| EP1246823A1 (de) | 1999-12-28 | 2002-10-09 | Pharmacopeia, Inc. | Pyrimidin- und triazin kinase-hemmer |
| EP1149583A3 (de) | 2000-04-13 | 2001-11-14 | Pfizer Products Inc. | Kombinationen bestehend aus Antagonisten des Corticotropin freisetzenden Faktors und Stoffen, die die Wachstumshormonsekretion fördern |
| US6518269B1 (en) | 2000-07-28 | 2003-02-11 | University Of Arizona Foundation | Cancer treatment |
| GEP20063915B (en) | 2000-11-17 | 2006-09-11 | Bristol Myers Squibb Co | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS |
| US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| US6670357B2 (en) | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| AU2002316421B2 (en) | 2001-06-26 | 2008-05-15 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-ALPHA expression |
| TW200300350A (en) | 2001-11-14 | 2003-06-01 | Bristol Myers Squibb Co | C-5 modified indazolylpyrrolotriazines |
| US7388009B2 (en) | 2002-04-23 | 2008-06-17 | Bristol-Myers Squibb Company | Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors |
| TW200306841A (en) | 2002-04-23 | 2003-12-01 | Bristol Myers Squibb Co | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
| PT1497019E (pt) | 2002-04-23 | 2015-09-10 | Bristol Myers Squibb Co | Compostos de pirrolotriazina anilina úteis como inibidores de quinase |
| TW200407143A (en) | 2002-05-21 | 2004-05-16 | Bristol Myers Squibb Co | Pyrrolotriazinone compounds and their use to treat diseases |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| TWI272271B (en) | 2002-07-19 | 2007-02-01 | Bristol Myers Squibb Co | Process for preparing certain pyrrolotriazine compounds |
| AU2003265349A1 (en) | 2002-08-02 | 2004-02-23 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| TW200420565A (en) | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| JP2006516653A (ja) | 2003-02-05 | 2006-07-06 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤ピロロトリアジンの製造方法 |
| US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
| US7102001B2 (en) | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
| MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| US7064203B2 (en) | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
-
2002
- 2002-11-06 US US10/289,010 patent/US6867300B2/en not_active Expired - Fee Related
-
2003
- 2003-11-03 CN CNB2003801082297A patent/CN100360532C/zh not_active Expired - Fee Related
- 2003-11-03 JP JP2004551735A patent/JP4662775B2/ja not_active Expired - Fee Related
- 2003-11-03 CA CA002505365A patent/CA2505365A1/en not_active Abandoned
- 2003-11-03 DE DE60330800T patent/DE60330800D1/de not_active Expired - Lifetime
- 2003-11-03 WO PCT/US2003/035220 patent/WO2004043912A2/en not_active Ceased
- 2003-11-03 KR KR1020057008063A patent/KR20050084961A/ko not_active Ceased
- 2003-11-03 BR BR0316056-4A patent/BR0316056A/pt not_active IP Right Cessation
- 2003-11-03 EP EP03781756A patent/EP1562949B1/de not_active Expired - Lifetime
- 2003-11-03 ES ES03781756T patent/ES2337571T3/es not_active Expired - Lifetime
- 2003-11-03 AU AU2003287514A patent/AU2003287514A1/en not_active Abandoned
- 2003-11-03 AT AT03781756T patent/ATE453645T1/de not_active IP Right Cessation
- 2003-11-03 MX MXPA05004748A patent/MXPA05004748A/es active IP Right Grant
- 2003-11-03 PL PL377112A patent/PL377112A1/pl not_active Application Discontinuation
- 2003-11-04 TW TW092130839A patent/TWI290555B/zh not_active IP Right Cessation
-
2004
- 2004-12-22 US US11/019,788 patent/US7211666B2/en not_active Expired - Fee Related
-
2005
- 2005-05-05 CO CO05043491A patent/CO5560547A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004043912A2 (en) | 2004-05-27 |
| US20050107462A1 (en) | 2005-05-19 |
| US7211666B2 (en) | 2007-05-01 |
| BR0316056A (pt) | 2005-09-27 |
| DE60330800D1 (de) | 2010-02-11 |
| MXPA05004748A (es) | 2005-08-03 |
| US6867300B2 (en) | 2005-03-15 |
| PL377112A1 (pl) | 2006-01-23 |
| JP4662775B2 (ja) | 2011-03-30 |
| CN100360532C (zh) | 2008-01-09 |
| AU2003287514A1 (en) | 2004-06-03 |
| CN1735615A (zh) | 2006-02-15 |
| EP1562949A2 (de) | 2005-08-17 |
| TWI290555B (en) | 2007-12-01 |
| TW200413382A (en) | 2004-08-01 |
| ES2337571T3 (es) | 2010-04-27 |
| EP1562949A4 (de) | 2007-09-12 |
| CO5560547A2 (es) | 2005-09-30 |
| KR20050084961A (ko) | 2005-08-29 |
| US20030186982A1 (en) | 2003-10-02 |
| EP1562949B1 (de) | 2009-12-30 |
| CA2505365A1 (en) | 2004-05-27 |
| JP2006514622A (ja) | 2006-05-11 |
| WO2004043912A3 (en) | 2004-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE453645T1 (de) | Verfahren zur herstellung von pyrrolotriazinverbindungen, die sich als kinaseinhibitoren eignen | |
| ATE425136T1 (de) | Verfahren zur herstellung substituierter 3-aryl- butyl-aminverbindungen | |
| NO20081941L (no) | Pyrazol [1,5-alfa]pyrimidinylderivater nyttige som kortikotropin-frigivende faktor (CRF) reseptorantagonister | |
| ATE444295T1 (de) | Verfahren zur herstellung von quaternäre n-alkyl morphinan alkaloid salzen | |
| ATE426594T1 (de) | Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase | |
| DE60104825D1 (de) | Verfahren zur herstellung von 6-substituierten (s)-nikotin-derivaten und zwischenverbindungen | |
| BR0318521A (pt) | arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados | |
| ATE299878T1 (de) | Verfahren zur herstellung von azacycloalkanoylaminothiazolen | |
| ATE397611T1 (de) | Verfahren zur herstellung von olanzapin | |
| DE602005026827D1 (de) | Verfahren zur herstellung von isoindolderivaten | |
| ATE359287T1 (de) | Ein verfahren zur herstellung von clopidogrel | |
| ATE310735T1 (de) | Verfahren zur herstellung von spirocyclischen tetronsäurederivaten | |
| ATE496038T1 (de) | Verfahren zur herstellung von quetiapin | |
| ATE280769T1 (de) | Verfahren zur herstellung von vitronectin- rezeptorantagonisten | |
| ATE370950T1 (de) | Verfahren zur herstellung von (1s,4r)-cis-4-(2- amino-6-chlor-9h-purin-9-yl)-2-cyclopenten-1- methanol | |
| DE60234279D1 (de) | Verfahren zur herstellung eines immunosuppresivums | |
| EP1302459A4 (de) | Verfahren zur herstellung von annelierten pyrrolen | |
| ATE300534T1 (de) | Verfahren und zwischenverbindungen zur herstellung von imidazopyridinen | |
| ATE221070T1 (de) | Verfahren zur herstelung von pirlindolehydrochlorid | |
| ATE423096T1 (de) | Verfahren zur herstellung von 2- azabicycloä3.3.0üoctan-3-carbonsäurederivaten | |
| ATE380183T1 (de) | Verfahren zur herstellung von phenyltetrazolderivaten | |
| DE60306361D1 (de) | Verfahren zur herstellung von benazeprilhydrochloride | |
| ATE425143T1 (de) | Verfahren zur herstellung von indolen | |
| ATE403418T1 (de) | Verfahren zur herstellung von festen dosierformen von amorphem valganciclovir-hydrochlorid | |
| ATE469119T1 (de) | Verfahren zur herstellung von polymorphen von sertralin hydrochlorid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |